Navigation Links
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
Date:5/14/2012

1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements.  Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons, including, but not limited to, results of clinical trials, regulatory actions by the Food and Drug Administration and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.

 

 PALATIN TECHNOLOGIES, INC.and Subsidiary

 Consolidated Statements of Operations

(unaudited)Three Months Ended March 31,Nine Months Ended March 31,2012201120122011REVENUES:Contract$
23,996$
,294$
2,705$
472,849Grant---846,768Total revenues23,99661,29462,7051,319,617OPERATING EXPENSES:Research and development4,705,6621,722,4329,683,1127,159,634General and administrative1,344,861955,5473,473,9903,226,798Total operating expenses6,050,5232,677,97913,157,10210,386,432Loss from operations(6,026,527)(2,616,685)(13,094,397)(9,066,815)OTHER INCOME (EXPENSE):Investment income5,95518,982
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2015)... Diego, CA (PRWEB) , ... July 24, 2015 , ... ... & Referral Center in support of stem cell therapy training and clinical opportunities. , ... this new opportunity to veterinarians in the San Diego area. Stem cell therapy is ...
(Date:7/24/2015)... Origin Agritech Limited (NASDAQ GS: SEED) ("Origin", or the "Company"), ... , today announced that the Company will report results ... 2015, before the market opens on Wednesday, August 5th, 2015. ... 5th, 2015, at 9:00 a.m. ET / 9:00 p.m. ... participate in the call, please dial the following numbers approximately ...
(Date:7/23/2015)... ANGELES , July 23, 2015 ImmunoCellular Therapeutics, ... to report financial results for the second quarter 2015 on ... a conference call and webcast on that day at 5:00 ... and provide a business update. The call will be hosted ...   , , , LIVE CALL: ...
(Date:7/23/2015)... , July 23, 2015 The Hong Kong ... given the prestigious accolade of "Most Innovative Technology ... world-class position in fostering innovation and technology development ... region.  The award has ... innovation and technology magazine and website with a ...
Breaking Biology Technology:VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 2VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 3Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 2Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 3ImmunoCellular Therapeutics to Report Second Quarter 2015 Financial Results on August 6, 2015 2HKSTP Wins Most Innovative Technology Hub at The New Economy Awards 2015 2HKSTP Wins Most Innovative Technology Hub at The New Economy Awards 2015 3
... 6 VIRxSYS Corporation announced today the publication ... Abundant Albumin Transcripts for Production of Therapeutic Proteins In ... The study describes a novel RNA therapy technique in which ... gene "hijacks" the albumin, causing it to produce the newly ...
... 6 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) ... has posted a new entry on his blog on ... recent meetings in Zurich, Switzerland, further development plans for ... for clinical-grade Oxycyte, and plans for raising additional capital. ...
... April 6 /PRNewswire/ - Orcrist Bio Inc. (ORC) ... today the approval of its Phase I, open-label, ... volunteers, by the European Competent Authority in Seville, ... assess the safety, tolerability, pharmacokinetics and pharmacodynamics (induction ...
Cached Biology Technology:VIRxSYS Publishes New Study on RNA Therapy 2Orcrist Bio Inc. Receives Approval from European Competent Authority to Initiate its Planned Phase I, Open-label, Single-ascending-dose, Safety Study of HYC750 2
(Date:7/21/2015)... 2015 Today, ZTE announced its Android smartphone ... as expected revenues in 2015 that relate to sales of FPC1025 ... of approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO ... manufacturer in China and we are proud ... 5 for Axon , its first ...
(Date:7/20/2015)... DENVER , July 20, 2015  Acuity ... Mobility Report: The Convergence of Commerce and Privacy" ... billion mobile biometric apps will be downloaded to ... users. The mobile biometrics market is projected to ... app revenue during the seven-year forecast period.    ...
(Date:7/9/2015)... Calif. , July 9, 2015  Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... Thursday, July 30, 2015 after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... release is available in German . ... in Freiburg have gained important insights for stem cell research ... to the development of new treatments. As Rolf Kemler,s research ... determines the length of the telomeres and a signalling pathway ...
... , Akron, Ohio, June 27, 2012 Expertise in fluid ... a new research center designed to help physicians better diagnose ... neck and shoulders. Chiari malformation is a disorder of ... brain and spinal fluid. UA engineers are able to ...
... animal scientists are working together to meet the challenges of ... experimental Biology on 28th June will demonstrate innovative techniques and ... issues, crop yields and diminishing fish stocks. , In ... the world,s four most important crops has fallen short of ...
Cached Biology News:When does a headache need an engineer to fix it? 2When does a headache need an engineer to fix it? 3
... siTrio siRNA --- a cocktail of ... gene of interestis our most popular product. ... than 75% knockdown of your target gene ... siRNA for transfection and confirmation of optimal ...
... offers a large collection of phage ... tissuea, cell lines, and mouse tissues. ... pHD9 vector. The size of cDNA ... from 200bp to 1000bp by gel ...
... A multi-purpose, high gel-strength agarose suitable for ... from conventional constant field to Pulsed Field ... gel strength and exclusion limits, Multi ABgarose ... reduced running times. This in turn means ...
7G10 anti-Fasciclin III...
Biology Products: